|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
<b>:</b> Accumulative evidence indicated that the pathologically accumulated metal ions (iron species and Mn<sup>3+</sup>) and abnormally up-regulated monoamine oxidase B (MAOB) activity induced oxidation of endogenous dopamine (DA) can lead to mitochondria impairment, lysosome dysfunction, proteasome inhibition, and selective DA neuron vulnerability, which is implicated in the pathogenesis of Parkinson's disease (PD).
|
31426448 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson's disease.
|
31268358 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Parkinson's disease (PD) is associated with elevated levels of hMAO-B in the brain, and MAO-B has been recognized a successful target for developing anti-PD drugs.
|
29339253 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
MAO-B increases with age as does predisposition towards PD which has also been linked to increased oxidative stress.
|
15247489 |
2004 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase-B (MAO-B) inhibitors are widely used in the treatment of Parkinson's disease.
|
28069007 |
2017 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MAOB levels were increased in degenerating putamen (+83%) and substantia nigra (+10%, non-significant) in multiple system atrophy; in caudate (+26%), putamen (+27%), frontal cortex (+31%) and substantia nigra (+23%) of progressive supranuclear palsy; and in frontal cortex (+33%), but not in substantia nigra of Parkinson's disease, a region we previously reported no increase in astrocyte protein markers.
|
29050386 |
2017 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
|
29578580 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO-B) is a validated drug target for Parkinson's disease.
|
29648817 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B inhibitors are currently widely used as symptomatic therapeutics for PD and, although somewhat controversial, these drugs may also exhibit disease-modifying properties.
|
29713806 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO B) inhibitors, which inhibit dopamine decomposition by antagonizing MAO B activity, are approved and widely used for clinical treatment of Parkinson's disease (PD).
|
30004136 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B-specific inhibitors such as some of the quinazolinone compounds investigated here may act as leads for the design of therapies for neurodegenerative disorders such as Parkinson's disease.
|
31115748 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B specific inhibitors such as those discovered here may be of interest in the treatment of neurodegenerative disorders such as Parkinson's disease.
|
31537422 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson's disease as monotherapy or adjuvant to levodopa.
|
31562557 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase type B inhibitors act in Parkinson's disease (PD) via potentiation of dopamine, but may also have neuroprotective effects by reducing oxidative damage.
|
31836905 |
2019 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease.
|
9596006 |
1998 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
A number of other candidate gene polymorphisms including cytochrome P450 2D6, N-acetyltransferase 2, monoamine oxidase-B and glutathione-s-transferase M1 are implicated in sporadic and familial cases and may also play a minor role in the aetiology of Parkinson's disease.
|
14732367 |
2004 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease.
|
29552556 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists.
|
29569037 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
An active role of monoamine oxidase B (MAO-B) in the pathogenesis of neurodegenerative disorders such as Parkinson's disease has been proposed as the enzyme is known to be a generator of free radicals which seem to be responsible for neuron oxidative damage.
|
10619718 |
1999 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
An allelic association study of monoamine oxidase B in Parkinson's disease.
|
7695241 |
1995 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As another mechanism of clinical efficacy, MAO B inhibitors such as selegiline are speculated to have neuroprotective effects to prevent progress of PD.
|
17447416 |
2006 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As the monoamine oxidase B (MAO B) and the histamine H<sub>3</sub> receptor (H<sub>3</sub>R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.
|
29477889 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.
|
9129714 |
1997 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
|
25034874 |
2014 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both monoamine oxidase B (MAO-B) and iron accumulation are associated with neurologic diseases including Parkinson's disease.
|
28685208 |
2017 |